Thymalfasin combined with chemo-immunotherapy aims to improve 3-year survival in TNBC
Background
Triple-negative breast cancer (TNBC) remains a highly aggressive malignancy, characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression. This lack of targetable receptors limits treatment options, making chemotherapy the primary systemic therapy. Despite recent advances with neoadjuvant chemo-immunotherapy regimens, a significant proportion of patients still harbor residual cancer burden (RCB) after treatment, leading to poor relapse-free and overall survival rates. There is an urgent need for strategies to enhance the efficacy of existing therapies and improve long-term outcomes for these high-risk patients. Immunomodulators like Thymalfasin, which can boost immune responses, are being explored to sensitize tumors to standard chemo-immunotherapy.
Study Design
This is a prospective, open-label, single-center, phase II, randomized controlled clinical trial. It enrolls patients with triple-negative breast cancer (TNBC) meeting criteria for neoadjuvant chemotherapy (tumor size T > 2 cm, lymph node involvement N+). The study compares two arms: an experimental group receiving Thymalfasin in combination with standard neoadjuvant chemotherapy and immunotherapy (including PD-1 inhibitors), versus a control group receiving standard neoadjuvant chemotherapy and immunotherapy alone. Primary endpoints are the 3-year event-free survival (EFS) and IFNγ elevation rates, aiming to validate Thymalfasin's sensitizing effect and safety.
Results
This ongoing phase II trial is currently active but not recruiting, meaning specific results regarding Thymalfasin's efficacy and safety are not yet available. The study is designed to compare the 3-year event-free survival (EFS) between the Thymalfasin combination arm and the control arm, as well as assess differences in IFNγ elevation rates. The primary objective is to validate the sensitizing effect of Thymalfasin when added to standard neoadjuvant chemotherapy and immunotherapy for TNBC. Data on these critical endpoints will be collected and analyzed upon completion of the trial, providing crucial insights into the potential benefits of this combination strategy.
Why It Matters
For TNBC patients, especially those at high risk of residual disease, new strategies to enhance treatment response are critical. Thymalfasin's potential to sensitize tumors to existing chemo-immunotherapy could significantly improve 3-year event-free survival, a key indicator of long-term prognosis. If successful, this trial could establish Thymalfasin as a valuable adjunct, potentially leading to a more robust and durable anti-tumor immune response. This could translate into a new protocol for TNBC, where Thymalfasin is integrated into standard neoadjuvant regimens to reduce recurrence rates and improve patient outcomes. The focus on IFNγ elevation suggests a mechanism of action via immune modulation, which could be a powerful tool against this aggressive cancer type.
thymalfasin
tnbc
breast-cancer
immunotherapy
chemotherapy
clinical-trial
